Clinical trial
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
NCT03340883 is registered in ClinicalTrials.gov with Chinook Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Chinook Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- November 15, 2017
- Completion date
- July 9, 2019
- Enrollment
- 21 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.